A dynamic prognostic model to predict survival in post–polycythemia vera myelofibrosis
- 1 April 2008
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 111 (7), 3383-3387
- https://doi.org/10.1182/blood-2007-11-121434
Abstract
Post–polycythemia vera myelofibrosis (post-PV MF) is a late evolution of PV. In 647 patients with PV, we found that leukocytosis leukocyte count > (15 × 109/L) at diagnosis is a risk factor for the evolution of post-PV MF. In a series of 68 patients who developed post-PV MF, median survival was 5.7 years. Hemoglobin level less than 100 g/L (10 g/dL) at diagnosis of post-PV MF was an independent risk factor for survival. The course of post-PV MF, however, is a dynamic process that implies a progressive worsening of clinical parameters. Using a multivariate Cox proportional hazard regression with time-dependent covariates, we found that a dynamic score based on hemoglobin level less than 100 g/L (10 g/dL), platelet count less than 100 × 109/L, and leukocyte count more than 30 × 109/L is useful to predict survival at any time from diagnosis of post-PV MF. The resulting hazard ratio of the score was 4.2 (95% CI: 2.4-7.7; P < .001), meaning a 4.2-fold worsening of survival for each risk factor acquired during follow up. In conclusion, leukocytosis at diagnosis of PV is a risk factor for evolution in post-PV MF. A dynamic score based on hemoglobin level, and platelet and leukocyte count predicts survival at any time from diagnosis of post-PV MF.Keywords
This publication has 25 references indexed in Scilit:
- JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trialsLeukemia, 2007
- Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disordersBlood, 2006
- High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertensionBlood, 2006
- The JAK2V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlatesBritish Journal of Haematology, 2005
- Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasiaBlood, 2005
- Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patientsBritish Journal of Haematology, 2004
- Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemiaThe American Journal of Medicine, 2004
- Allogeneic hematopoietic stem cell transplantation for myelofibrosisBlood, 2003
- Polycythemia vera: myths, mechanisms, and managementBlood, 2002
- Myelofibrosis with Myeloid MetaplasiaNew England Journal of Medicine, 2000